BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 31397525)

  • 21. Proteogenomic Platform for Identification of Tumor Specific Antigens.
    Faktor J; Hernychová L; Vojtěšek B; Hupp T
    Klin Onkol; 2018; 31(Suppl 2):102-107. PubMed ID: 31023032
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Exploring the Immunogenicity of Noncanonical HLA-I Tumor Ligands Identified through Proteogenomics.
    Lozano-Rabella M; Garcia-Garijo A; Palomero J; Yuste-Estevanez A; Erhard F; Farriol-Duran R; Martín-Liberal J; Ochoa-de-Olza M; Matos I; Gartner JJ; Ghosh M; Canals F; Vidal A; Piulats JM; Matías-Guiu X; Brana I; Muñoz-Couselo E; Garralda E; Schlosser A; Gros A
    Clin Cancer Res; 2023 Jun; 29(12):2250-2265. PubMed ID: 36749875
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Proteogenomic Analysis Unveils the HLA Class I-Presented Immunopeptidome in Melanoma and EGFR-Mutant Lung Adenocarcinoma.
    Qi YA; Maity TK; Cultraro CM; Misra V; Zhang X; Ade C; Gao S; Milewski D; Nguyen KD; Ebrahimabadi MH; Hanada KI; Khan J; Sahinalp C; Yang JC; Guha U
    Mol Cell Proteomics; 2021; 20():100136. PubMed ID: 34391887
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Determinants for Neoantigen Identification.
    Garcia-Garijo A; Fajardo CA; Gros A
    Front Immunol; 2019; 10():1392. PubMed ID: 31293573
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cancer immunotherapy. A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells.
    Carreno BM; Magrini V; Becker-Hapak M; Kaabinejadian S; Hundal J; Petti AA; Ly A; Lie WR; Hildebrand WH; Mardis ER; Linette GP
    Science; 2015 May; 348(6236):803-8. PubMed ID: 25837513
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mapping the tumour human leukocyte antigen (HLA) ligandome by mass spectrometry.
    Freudenmann LK; Marcu A; Stevanović S
    Immunology; 2018 Jul; 154(3):331-345. PubMed ID: 29658117
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Neoantigen identification strategies enable personalized immunotherapy in refractory solid tumors.
    Chen F; Zou Z; Du J; Su S; Shao J; Meng F; Yang J; Xu Q; Ding N; Yang Y; Liu Q; Wang Q; Sun Z; Zhou S; Du S; Wei J; Liu B
    J Clin Invest; 2019 May; 129(5):2056-2070. PubMed ID: 30835255
    [TBL] [Abstract][Full Text] [Related]  

  • 28. NEPdb: A Database of T-Cell Experimentally-Validated Neoantigens and Pan-Cancer Predicted Neoepitopes for Cancer Immunotherapy.
    Xia J; Bai P; Fan W; Li Q; Li Y; Wang D; Yin L; Zhou Y
    Front Immunol; 2021; 12():644637. PubMed ID: 33927717
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cross-HLA targeting of intracellular oncoproteins with peptide-centric CARs.
    Yarmarkovich M; Marshall QF; Warrington JM; Premaratne R; Farrel A; Groff D; Li W; di Marco M; Runbeck E; Truong H; Toor JS; Tripathi S; Nguyen S; Shen H; Noel T; Church NL; Weiner A; Kendsersky N; Martinez D; Weisberg R; Christie M; Eisenlohr L; Bosse KR; Dimitrov DS; Stevanovic S; Sgourakis NG; Kiefel BR; Maris JM
    Nature; 2021 Nov; 599(7885):477-484. PubMed ID: 34732890
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antigen presentation profiling reveals recognition of lymphoma immunoglobulin neoantigens.
    Khodadoust MS; Olsson N; Wagar LE; Haabeth OA; Chen B; Swaminathan K; Rawson K; Liu CL; Steiner D; Lund P; Rao S; Zhang L; Marceau C; Stehr H; Newman AM; Czerwinski DK; Carlton VE; Moorhead M; Faham M; Kohrt HE; Carette J; Green MR; Davis MM; Levy R; Elias JE; Alizadeh AA
    Nature; 2017 Mar; 543(7647):723-727. PubMed ID: 28329770
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Identification of the Cryptic HLA-I Immunopeptidome.
    Erhard F; Dölken L; Schilling B; Schlosser A
    Cancer Immunol Res; 2020 Aug; 8(8):1018-1026. PubMed ID: 32561536
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Proteogenomic analysis reveals RNA as a source for tumor-agnostic neoantigen identification.
    Tretter C; de Andrade Krätzig N; Pecoraro M; Lange S; Seifert P; von Frankenberg C; Untch J; Zuleger G; Wilhelm M; Zolg DP; Dreyer FS; Bräunlein E; Engleitner T; Uhrig S; Boxberg M; Steiger K; Slotta-Huspenina J; Ochsenreither S; von Bubnoff N; Bauer S; Boerries M; Jost PJ; Schenck K; Dresing I; Bassermann F; Friess H; Reim D; Grützmann K; Pfütze K; Klink B; Schröck E; Haller B; Kuster B; Mann M; Weichert W; Fröhling S; Rad R; Hiltensperger M; Krackhardt AM
    Nat Commun; 2023 Aug; 14(1):4632. PubMed ID: 37532709
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Increased expression of peptides from non-coding genes in cancer proteomics datasets suggests potential tumor neoantigens.
    Xiang R; Ma L; Yang M; Zheng Z; Chen X; Jia F; Xie F; Zhou Y; Li F; Wu K; Zhu Y
    Commun Biol; 2021 Apr; 4(1):496. PubMed ID: 33888849
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Proteogenomic analysis identifies neoantigens and bacterial peptides as immunotherapy targets in colorectal cancer.
    Yao P; Gao M; Hu W; Wang J; Wang Y; Wang Q; Ji J
    Pharmacol Res; 2024 Jun; 204():107209. PubMed ID: 38740147
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prioritizing candidate peptides for cancer vaccines through predicting peptide presentation by HLA-I proteins.
    Zhou LY; Zou F; Sun W
    Biometrics; 2023 Sep; 79(3):2664-2676. PubMed ID: 35833513
    [TBL] [Abstract][Full Text] [Related]  

  • 36. CD8
    Kikuchi Y; Tokita S; Hirama T; Kochin V; Nakatsugawa M; Shinkawa T; Hirohashi Y; Tsukahara T; Hata F; Takemasa I; Sato N; Kanaseki T; Torigoe T
    Cancer Immunol Res; 2021 Nov; 9(11):1342-1353. PubMed ID: 34433589
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Proteogenomics meets cancer immunology: mass spectrometric discovery and analysis of neoantigens.
    Polyakova A; Kuznetsova K; Moshkovskii S
    Expert Rev Proteomics; 2015; 12(5):533-41. PubMed ID: 26175083
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Targeting Neoantigens for Personalised Immunotherapy.
    Pritchard AL
    BioDrugs; 2018 Apr; 32(2):99-109. PubMed ID: 29516371
    [TBL] [Abstract][Full Text] [Related]  

  • 39. IFNγ Modulates the Immunopeptidome of Triple Negative Breast Cancer Cells by Enhancing and Diversifying Antigen Processing and Presentation.
    Goncalves G; Mullan KA; Duscharla D; Ayala R; Croft NP; Faridi P; Purcell AW
    Front Immunol; 2021; 12():645770. PubMed ID: 33968037
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Applications of Immunogenomics to Cancer.
    Liu XS; Mardis ER
    Cell; 2017 Feb; 168(4):600-612. PubMed ID: 28187283
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.